Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced XXXX : A Phase II Study.

@entity1 @entity137 @entity2167 @entity63 @entity5 @entity900 @entity2622 @entity1311 @entity56 @entity583 @entity3847 @entity902 @entity204
OBJECTIVE: To assess the efficacy and @entity137 profile of dose-dense @entity900 -based neoadjuvant chemotherapy (NACT) followed by radical surgery in @entity1 affected by locally advanced @entity5 . METHODS: @entity1 affected by @entity2622 FIGO (International Federation of Obstetrics and Gynecology) stage @entity3847 were enrolled into the study. The treatment schedule consisted of 5 cycles of intravenous @entity1311 60 mg/m(2) plus @entity900 60 mg/m(2) every 10 days; @entity1 were then submitted to radical hysterectomy and pelvic lymphadenectomy. RESULTS: From January 2011 to March 2013, 22 @entity1 were enrolled. Median age was 47 (26-83) years. FIGO stages included 1 IIA, 15 IIB, 1 IIIA, and 5 IIIB. Ninety-one percent of @entity1 completed all the 5 planned cycles of NACT. Three @entity1 experienced @entity56 to @entity1311 . Grade 3-4 hematological @entity137 was observed in 18% of cases. In 3 cases, grade 3-4 extra-hematological adverse and life-threatening events were reported (1 @entity2167 , 1 transient @entity63 attack, and 1 @entity583 ). No treatment-related @entity204 occurred. The operability rate was 86.4%. The overall response rate was 52.6%: 5 @entity1 (26.3%) experienced clinical complete response, and 5 (26.3%) showed a clinical partial response. Stable disease was observed in 47.4% of @entity1 , with no progressive disease recorded. Pathological response was observed in 57.9% of cases. Six out of 19 (31.6%) @entity1 were submitted to adjuvant treatment. CONCLUSION: Dose-dense @entity900 -based NACT showed a response rate in approximately half of @entity1 . However, in consideration of the reported extra-hematological @entity137 , further studies on and new strategies with dose-dense @entity902 -based NACT are required to improve outcome in @entity5 @entity1 .    2015 S. Karger AG, Basel.
